DD272034A5 - Verfahren zur herstellung einer praeparation zur regulierung des gewebewachstums - Google Patents

Verfahren zur herstellung einer praeparation zur regulierung des gewebewachstums Download PDF

Info

Publication number: DD272034A5
Authority: DD; German Democratic Republic
Prior art keywords: solution; biotin; acetyl; tissue growth; regulation
Prior art date: 1985-10-08

Application number

DD86295099A

Other languages

German (de)

English (en)

Inventor

Neil G C Hendry

Original Assignee

Hendry,Neil Geddes Clarkson,Gb

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-08

Filing date

1986-10-08

Publication date

1989-09-27

1986-10-08 Application filed by Hendry,Neil Geddes Clarkson,Gb filed Critical Hendry,Neil Geddes Clarkson,Gb

1989-09-27 Publication of DD272034A5 publication Critical patent/DD272034A5/de

Links

230000008467 tissue growth Effects 0.000 title claims abstract description 12
230000001105 regulatory effect Effects 0.000 title claims abstract description 6
238000004519 manufacturing process Methods 0.000 title abstract description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 22
238000002360 preparation method Methods 0.000 claims abstract description 14
229960002685 biotin Drugs 0.000 claims abstract description 11
235000020958 biotin Nutrition 0.000 claims abstract description 11
239000011616 biotin Substances 0.000 claims abstract description 11
150000001768 cations Chemical class 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims abstract description 6
229910052751 metal Inorganic materials 0.000 claims abstract description 5
239000002184 metal Substances 0.000 claims abstract description 5
150000001450 anions Chemical class 0.000 claims abstract description 4
150000001615 biotins Chemical class 0.000 claims abstract description 4
238000006467 substitution reaction Methods 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 27
230000033228 biological regulation Effects 0.000 claims description 8
239000007787 solid Substances 0.000 claims description 8
239000002244 precipitate Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 3
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
238000007710 freezing Methods 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
150000002337 glycosamines Chemical group 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
239000000047 product Substances 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims 2
238000004108 freeze drying Methods 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
239000012042 active reagent Substances 0.000 claims 1
MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 claims 1
238000001816 cooling Methods 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
210000004027 cell Anatomy 0.000 description 22
239000000203 mixture Substances 0.000 description 17
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 13
230000000694 effects Effects 0.000 description 12
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 11
230000035876 healing Effects 0.000 description 11
229950006780 n-acetylglucosamine Drugs 0.000 description 11
239000000243 solution Substances 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 9
230000006378 damage Effects 0.000 description 8
230000003211 malignant effect Effects 0.000 description 8
239000000463 material Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
208000014674 injury Diseases 0.000 description 6
108010044467 Isoenzymes Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000001035 drying Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
239000002523 lectin Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
108700023418 Amidases Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000777300 Congiopodidae Species 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
-1 Glycidyl histidyl lysine Chemical compound 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
PLJAKLUDUPBLGD-VLWZLFBZSA-N N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-aldehydo-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O PLJAKLUDUPBLGD-VLWZLFBZSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
102000005922 amidase Human genes 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000459 effect on growth Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000005741 malignant process Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
230000008481 normal tissue growth Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD86295099A 1985-10-08 1986-10-08 Verfahren zur herstellung einer praeparation zur regulierung des gewebewachstums DD272034A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB858524807A GB8524807D0 (en)	1985-10-08	1985-10-08	Tissue growth regulation

Publications (1)

Publication Number	Publication Date
DD272034A5 true DD272034A5 (de)	1989-09-27

Family

ID=10586368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD86295099A DD272034A5 (de)	1985-10-08	1986-10-08	Verfahren zur herstellung einer praeparation zur regulierung des gewebewachstums

Country Status (10)

Country	Link
EP (1)	EP0239607A1 (cs)
JP (1)	JPS63501077A (cs)
AU (1)	AU606038B2 (cs)
CA (1)	CA1289885C (cs)
CS (1)	CS265224B2 (cs)
DD (1)	DD272034A5 (cs)
GB (1)	GB8524807D0 (cs)
IN (1)	IN168295B (cs)
WO (1)	WO1987002244A1 (cs)
ZA (1)	ZA867664B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5273900A (en) *	1987-04-28	1993-12-28	The Regents Of The University Of California	Method and apparatus for preparing composite skin replacement
CA1318592C (en) *	1988-11-18	1993-06-01	University Of British Columbia	N-acetyl glucosamine as a cytoprotective agent
US5192750A (en) *	1992-01-28	1993-03-09	The University Of British Columbia	Method and composition for treatment of food allergy
US5229374A (en) *	1992-01-28	1993-07-20	Burton Albert F	Method for treatment of lower gastrointestinal tract disorders
US5217962A (en) *	1992-01-28	1993-06-08	Burton Albert F	Method and composition for treating psoriasis
US6046179A (en) *	1998-04-17	2000-04-04	Murch; Simon	Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
US6159485A (en)	1999-01-08	2000-12-12	Yugenic Limited Partnership	N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
CN1173706C (zh)	2001-02-28	2004-11-03	中国人民解放军第三军医大学	N-乙酰-d-氨基葡萄糖在制备治疗宫颈糜烂药物中的应用
CN1199645C (zh)	2002-08-13	2005-05-04	中国人民解放军第三军医大学	N－乙酰－d－氨基葡萄糖在制备治疗泌尿生殖道感染药物中的应用
WO2005025581A1 (fr) *	2003-09-17	2005-03-24	Third Military Medical University, Chinese People's Liberation Army, P.R. Of China	Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
CA2551613A1 (en) *	2004-05-21	2005-12-01	Tottori University	A composition comprising n-acetyl-d-glucosamine for treatment of wound
ITBS20070178A1 (it) *	2007-11-15	2009-05-16	Paoli Ambrosi Gianfranco De	Composizione per uso farmaceutico e/o cosmetico e/o in forma di dispositivo medico per favorire processi di cicatrizzazione, per il trattamento di cicatrici ipertrofiche e per migliorare le proprieta' biomeccaniche della cute

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3232836A (en) *	1959-08-24	1966-02-01	Pfizer & Co C	Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine

1985
- 1985-10-08 GB GB858524807A patent/GB8524807D0/en active Pending
1986
- 1986-10-07 CA CA000520028A patent/CA1289885C/en not_active Expired - Lifetime
- 1986-10-08 ZA ZA867664A patent/ZA867664B/xx unknown
- 1986-10-08 AU AU64094/86A patent/AU606038B2/en not_active Ceased
- 1986-10-08 JP JP61505290A patent/JPS63501077A/ja active Pending
- 1986-10-08 WO PCT/GB1986/000607 patent/WO1987002244A1/en not_active Ceased
- 1986-10-08 DD DD86295099A patent/DD272034A5/de not_active IP Right Cessation
- 1986-10-08 CS CS867292A patent/CS265224B2/cs unknown
- 1986-10-08 EP EP86905906A patent/EP0239607A1/en not_active Withdrawn
- 1986-10-08 IN IN896/DEL/86A patent/IN168295B/en unknown

Also Published As

Publication number	Publication date
WO1987002244A1 (en)	1987-04-23
CA1289885C (en)	1991-10-01
AU606038B2 (en)	1991-01-31
IN168295B (cs)	1991-03-09
EP0239607A1 (en)	1987-10-07
GB8524807D0 (en)	1985-11-13
CS265224B2 (en)	1989-10-13
JPS63501077A (ja)	1988-04-21
CS729286A2 (en)	1989-01-12
AU6409486A (en)	1987-05-05
ZA867664B (en)	1987-05-27

Legal Events

Date	Code	Title	Description
2001-08-02	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69327544T2 (de)	2000-08-24	Mischungen zum schutz und regenierung von geweben
DE60032543T2 (de)	2007-10-04	Topisch verabreichbare Zinkzusammensetzungen
DE69909794T2 (de)	2004-06-09	Verwendung eines dipeptids für wiederherstellungsprozesse
DE1617317A1 (de)	1971-03-25	Verfahren zur Herstellung von aktiven,die Wundheilung foerdernden Wirkstoffen aus Knorpelmasse
DE69414904T2 (de)	1999-05-12	Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen
DE68916430T2 (de)	1994-10-13	Arzneimittelzubereitung zur behandlung von mastitis bei tier und mensch.
DD272034A5 (de)	1989-09-27	Verfahren zur herstellung einer praeparation zur regulierung des gewebewachstums
DE3784695T2 (de)	1993-10-14	Gebrauch von Gramineenextrakten als Arzneimittel.
DE1720120A1 (de)	1971-07-22	Injizierbare Zusatzmittel,Verfahren ihrer Herstellung und Verwendung und neue medizinische Zusammensetzungen,die dieses Zusatzmittel enthalten
DE69825279T2 (de)	2005-08-04	Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
WO1997034929A1 (de)	1997-09-25	Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren
EP0176769A2 (de)	1986-04-09	Carcinom-Therapeutikum
DE3850262T2 (de)	1995-01-26	Verfahren zur herstellung einer physiologisch aktiven substanz aus samenschalen von föhren und ein gegen infektionen aktives mittel, hauptsächlich auf der basis von diesem extrakt.
DE3220326C2 (de)	1985-10-10	Carcinom-Therapeutikum
DE2619100A1 (de)	1977-11-10	Verwendung von glucuronsaeure oder glucuronsaeure-gamma-lacton als hemmstoff fuer beta-glucuronidase
DE68905076T2 (de)	1993-10-14	Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
EP0595297A1 (de)	1994-05-04	Ligninpolymerzusammensetzung zur Behandlung von Hautproblemen
DE3225597A1 (de)	1983-02-03	Verfahren zur herstellung eines gewebepraeparates
DE2349186C2 (de)	1982-11-11	Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion
DE69900336T2 (de)	2002-06-27	Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen
DE1086012B (de)	1960-07-28	Verfahren zur Herstellung von protrahiert wirkenden Vitamin-B-Praeparaten
CH690816A5 (de)	2001-01-31	Verwendung eines Teil- oder Vollextrates aus nicht fermentierter Camellia sinensis L. zur Herstellung eines Medikamentes, eines Medizinproduktes, eines kosmetischen Präparates oder eines Nahrungsergänzungsproduktes.
DE2934090A1 (de)	1981-03-12	Therapie der hyperkeratotischen hauterkrankungen.
DE3417022C2 (cs)	1988-06-16
DE1947896A1 (de)	1970-09-17	Pharmazeutische Zubereitungen und ihre Herstellung